Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, Amiens, France.
Department of Gerontology, CHU Amiens-Picardie, Amiens, France.
Vaccine. 2022 Jan 24;40(3):531-535. doi: 10.1016/j.vaccine.2021.11.086. Epub 2021 Dec 3.
Coronavirus disease 2019 (COVID-19) is associated with increased morbidity and mortality in older adults. Although the advent of the first vaccines has significantly reduced these rates, data on older adults in clinical trials are scarce.
We quantified and compared the humoral response in individuals with vs. without pre-existing seropositivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in a cohort of 69 patients living in a nursing home and who had received the recommended two doses of the Comirnaty (Pfizer-BioNTech®) vaccine.
All 69 patients (100%) tested positive for antibodies against SARS-CoV-2 at 2 months post-vaccination. Residents with a pre-vaccination infection had significantly higher titers of anti-spike 1 IgG than those with no prior infection (median [interquartile range]: 55,726 [14463-78852] vs. 1314 [272-1249] arbitrary units, respectively; p < 0.001). The same result was observed for neutralizing antibodies titers (704 [320-1280] vs. 47 [20-40] respectively; p < 0.001). Between the pre-vaccination and post-vaccination periods, for IgG and neutralizing antibodies, we observed a 49 and 8-fold increase respectively. In comparison to the wild-type Receptor Binding Domain (RBD), the binding capacity of these vaccine sera was significantly decreased on the B.1.351 and P.1 variants RBD but not decreased with respect to the B.1.1.7 RBD. Although all nursing home residents developed a humoral response following Comirnaty vaccine, its intensity appeared to depend on the pre-vaccination serological status.
Our results raise the question of how many doses of vaccine should be administered in older and how long the protection will be effective.
2019 年冠状病毒病（COVID-19）与老年人发病率和死亡率增加有关。尽管第一批疫苗的问世显著降低了这些比率，但临床试验中关于老年人的数据却很少。
我们在一个居住在养老院且接受了两剂辉瑞疫苗（Comirnaty）的 69 名患者队列中，量化并比较了有与无 SARS-CoV-2 既往血清阳性的个体的体液反应。
所有 69 名患者（100%）在接种疫苗后 2 个月均检测出针对 SARS-CoV-2 的抗体呈阳性。接种疫苗前感染的居民抗刺突 1 IgG 滴度明显高于无既往感染的居民（中位数[四分位间距]：55726[14463-78852]比 1314[272-1249]个单位，分别；p<0.001）。中和抗体滴度也观察到同样的结果（704[320-1280]比 47[20-40]，分别；p<0.001）。在接种疫苗前后期间，IgG 和中和抗体分别增加了 49 倍和 8 倍。与野生型受体结合域（RBD）相比，这些疫苗血清对 B.1.351 和 P.1 变体 RBD 的结合能力显著降低，但对 B.1.1.7 RBD 的结合能力并未降低。尽管所有养老院居民在接受辉瑞疫苗后均产生了体液反应，但反应强度似乎取决于接种疫苗前的血清学状态。
我们的结果提出了一个问题，即应该给老年人接种多少剂疫苗，以及保护作用将持续多久。
